Late mortality among survivors of childhood acute lymphoblastic leukemia diagnosed during 1971–2008 in Denmark, Finland, and Sweden: A population-based cohort study

An interesting article from Sørensen et al. about long term survival from childhood ALL (acute lymphoblastic leukemia). According to this article the long term results have improved decade after decade. Still there is space for improvements. Even if it is a small part of the whole ALL treatment protocol, it is worth having the lumbar punctures right the first time.

“Among ALL survivors, it was found that late mortality continued to decrease over treatment decades. This was highly attributable to a decrease in mortality from relapse.”

Read the publication from here: Late mortality among survivors of childhood acute lymphoblastic leukemia diagnosed during 1971–2008 in Denmark, Finland, and Sweden: A population-based cohort study Pediatr Blood Cancer. 2022;

Gitte V. Sørensen1,2 Federica Belmonte3 Friederike Erdmann4,5 Hanna Mogensen6 Vanna Albieri3 Anna S. Holmqvist7 Laura Madanat-Harjuoja8 Mats Talbäck6 Mats M. Heyman9 Nea Malila8 Maria Feychting6
Kjeld Schmiegelow10 Jeanette F. Winther2,4 Henrik Hasle1

1 Department of Pediatrics and Adolescent Medicine, Aarhus University Hospital, Aarhus, Denmark
2 Department of Clinical Medicine, Faculty of Health, Aarhus University and University Hospital, Aarhus, Denmark
3 Unit of Statistics and Data Analysis, Danish Cancer Society Research Center, Copenhagen, Denmark
4 Childhood Cancer Research Group, Danish Cancer Society Research Center, Copenhagen, Denmark
5 Division of Childhood Cancer Epidemiology, Institute of Medical Biostatistics, Epidemiology and Informatics, University Medical Center of the Johannes Gutenberg
University Mainz, Mainz, Germany
6 Unit of Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
7 Department of Clinical Sciences, Lund University, Pediatric Oncology and Hematology, Skåne University Hospital, Lund, Sweden
8 Finnish Cancer Registry, Helsinki, Finland
9 Childhood Cancer Research Unit, Department of Women’s and Children’s Health, Karolinska Institutet, Stockholm, Sweden
10 Institute of Clinical Medicine, Faculty of Medicine, University of Copenhagen, Copenhagen, Denmark

 

Älyneulan hyödyt

Injeq on tutkinut lumbaalipunktioiden suorittamista Suomessa ja aiheesta on nyt julkaistu tiivis selvitys.  Selvityksessä pohditaan mm. punktion jälkeisten päänsärkyjen sekä […]
Read more »

Injeq is one of the Europe’s Top 5 Medical Device Companies to Watch in 2023

Healthcare advancements that were mere ideas decades ago are coming to fruition, proving to be much more valuable to saving […]
Read more »

The 3rd part of Sievänen’s trilogy about traumatic lumbar punctures is out now: Incidence of traumatic lumbar punctures in adults: the impact of a patient’s first procedure

We are happy to announce that the last part of Sievänen’s traumatic lumbar punctures’ trilogy is now published. Two factors […]
Read more »

Päivi Lehtonen starting as Injeq’s new Sales Director in April

The current CEO of Teivo, Päivi Lehtonen, will start as Injeq’s new Sales Director in the beginning of April. Päivi […]
Read more »

We are excited to join the biggest German neurology event Neurowoche 2022

We are excited to join the biggest annual German neurology event Neurowoche 2022 with our distributor Ecumed. The congress takes […]
Read more »

Injeq participating Italian Neonatology congress SIN

Injeq is happy to join our Italian distributor Euromed at SIN – XXVIII Italian Neonatology Congress in beautiful Firenze. Come […]
Read more »